Mark Soloway

Last updated

Mark Soloway
Born1943 (age 81–82)
Midwest
Education
Occupation Surgeon
Known forProstate, bladder and kidney cancer research
Medical career
ProfessionUrologist
Institutions
Sub-specialties Prostate, bladder and kidney cancer
Awards

Dr. Mark S. Soloway (born 1943) is an American urologist and professor emeritus of urology. His work has focused on prostate, bladder, and kidney cancer research. He served as a professor and chairman of the Department of Urology at the University of Miami Miller School of Medicine, and as chief of urologic oncology at Memorial Hospital in Hollywood, Florida.

Contents

Soloway graduated from Case Western Reserve University School of Medicine, in Cleveland, Ohio, and completed his residency in urology at University Hospitals of Cleveland. He completed a two-year surgery branch fellowship at the National Cancer Institute (NCI) of the National Institute of Health (NIH) in Bethesda, Maryland. There, he developed an animal model to investigate the efficacy of several investigative chemotherapeutic drugs for bladder cancer. He later returned to Case Western Reserve to complete his residency in urology. [1]

Early life and education

Mark Soloway was born in the Midwest in 1943. [2] [3] In 1964, he received a bachelor's degree in biology from Northwestern University in Chicago. [4] He graduated from the Case Western Reserve University School of Medicine in Cleveland in 1968. [4] [5] While there, neurosurgeon Robert J. White reportedly influenced his interest in translational research. [3]

Early career

In 1968, Soloway conducted a two-year clinical fellowship at the National Cancer Institute (NCI) of the National Institutes of Health (NIH) in Bethesda, Maryland, specializing in urology. [3] [5] He developed an animal model for bladder cancer to research treatments for locally advanced or spreading bladder cancer. [5] [6] [7] This model, induced by the chemical FANFT in mice, allowed him to investigate the effectiveness of several experimental chemotherapy drugs for bladder cancer. [8] [9] [a] He also investigated the hypothesis that the high rate of local recurrence of bladder lining tumors may result from implantation of tumor cells on the urothelial surface following endoscopic resection of bladder tumors. [3] [10] [b] By developing an animal test for bladder tumor placement, Soloway's research contributed to the understanding that urothelial injury creates an environment for tumor implantation and supported the use of early intravesical chemotherapy following transurethral resection of a bladder tumor. [12] [13] [c] [15] This included his research on cis-diamminedichloro platinum, a type of cancer drug known as cisplatin. [16] [17] [18] After completing his fellowship, Soloway returned to Case Western Reserve to complete his residency in urology. [3] [5] He then joined the University of Tennessee. [19] His research also included early studies on combining chemotherapy and radiation. [20] [21]

Later career

From 1991 to 2010, Soloway served as a professor and the chairman of the University of Miami Miller School of Medicine Department of Urology. [5] In 2014, he became chief of urologic oncology at Memorial Hospital in Hollywood, Florida. [22] Soloway was among the early urologic oncologists to incorporate flexible cystoscopy into his practice. [23]

Transrectal ultrasonography for prostate cancer

Soloway's prostate cancer research includes work related to diagnosis, treatment, and management:

Soloway promoted the TRUS biopsy method for use in urologists' outpatient clinics. [24] [25] [26] He also contributed to the popularization of the periprostatic nerve block to minimize biopsy discomfort. [27] [28] [29]

Evaluating androgen deprivation

During the 1980s and early 1990s, a high percentage of men with prostate cancer were diagnosed with locally advanced disease. LHRH analogues were increasingly used as initial treatment. To assess the efficacy of neoadjuvant androgen deprivation therapy before prostatectomy in improving progression-free and overall survival, Soloway initiated a prospective randomized trial involving a multi-institutional group. [30] [31] This trial indicated that while the surgical margin rate was lower for men who received androgen deprivation before prostatectomy, there was no improvement in progression-free or overall survival. [32] [31] [d]

Positive surgical margins

Soloway's clinical research has also focused on the relationship between positive surgical margins and the preservation of the bladder neck and approach to the seminal vesicles. His 1996 publication on this topic detailed pathological analysis of the location and consequences of positive surgical margins. [33] In a paper published in The Journal of Urology, he reported that the recurrence rate was 20% in his patient cohort with a positive surgical margin, suggesting that routine adjuvant radiation therapy might overtreat a majority of these patients. [34] [35] Regarding urinary continence, Soloway has advocated for bladder neck preservation during radical retropubic prostatectomy to enhance urinary continence without compromising cancer control. [36] [37] Soloway and M. Manoharan collaborated on techniques to minimize the side effects of radical prostatectomy, including the use of a lower abdominal transverse incision to potentially reduce pain and enhance recovery. [38] Their work also indicated that many patients may not require a drain [39] [40] [41] and that an inguinal hernia could be repaired during the same operation as a radical prostatectomy using this transverse incision. [42] [43]

Watchful waiting approach (active surveillance)

With the advent of PSA testing and early detection of prostate cancer, Soloway advocated for active surveillance for patients with low-risk, low-volume Gleason 6 prostate cancer who adhered to careful monitoring, citing concerns about overtreatment. In 2000, he published a series of patients, including those eligible for watchful waiting and active surveillance, reporting that a low percentage of these patients subsequently underwent treatment. [44] Using a stricter definition for active surveillance, Soloway's group reported that less than 15% of these prostate cancer patients proceeded to treatment. [45] This series was later updated in European Urology to include quality of life parameters, maintaining a consistent rate of 15% progressing to treatment.

Work on renal tumors

Soloway collaborated with Gaetano Ciancio, a former resident and co-faculty member, on kidney cancer research. They developed a surgical approach for large renal tumors, particularly those with tumor extension into the vena cava. Ciancio, a urologist fellowship-trained in renal and liver transplantation, worked with Soloway to reduce perioperative morbidity and mortality associated with these tumor masses. Their approach aimed to integrate surgical techniques from liver transplantation to increase vena cava exposure, intending to reduce blood loss and avoid circulatory arrest. They have published articles on this technique since 2000. [46] Their recent publications provide updates on their step-by-step approach to minimizing complications related to renal cell carcinoma with vena cava thrombus, highlighting improvements in safety and reduction in operative mortality and morbidity. This technique is intended for duplication in tertiary medical centers with liver transplant surgeons.

Cancer support group

Soloway established one of the early prostate cancer support groups in Memphis, Tennessee. In 1992, he co-authored one of the initial quality of life (QOL) studies [47] examining patient preference regarding LHRH versus orchiectomy for advanced disease. In 1995, Soloway and colleagues published a study on QOL implications of surgical management versus radiation therapy for localized prostate cancer. [48] Soloway has also researched the psychosocial and sexual implications of this disease on patients and their partners. [49]

Awards and honors

Soloway's awards include:

Selected publications

Notes

  1. ↑ After more than thirty years, this transplantable tumor model, later established as the MBT-2 tumor and its more malignant derivative MBT-9, are still being used by researchers all over the world to test experimental and targeted therapeutic agents.[ citation needed ] Soloway's research was supported by NIH funding throughout his residency in Urology at Case Western Reserve University and as faculty at the University of Tennessee Center for the Health Sciences. [3]
  2. ↑ The bladder urothelium is generally dormant but regenerates following injury. [11]
  3. ↑ Twenty years later, a series of prospective randomized clinical trials have firmly established the benefit of post-TURBT intravesical chemotherapy. [14]
  4. ↑ Other groups who later performed similar studies have substantiated these results. [ citation needed ]

References

  1. ↑ "Emeritus Member | Mark Soloway, MD, FACS". Bladder Cancer Advocacy Network. Retrieved January 5, 2025.
  2. ↑ "Mark Soloway — OfficialUSA.com Records". www.officialusa.com. Archived from the original on August 8, 2024. Retrieved August 5, 2024.
  3. 1 2 3 4 5 6 Soloway, M. S. (February 2009). "Legends in urology" (PDF). Canadian Journal of Urology. 16 (1): 4447–4449. PMID   19222879. Archived from the original (PDF) on July 2, 2024.
  4. 1 2 "Mark Soloway". health.usnews.com. Archived from the original on August 9, 2024. Retrieved August 5, 2024.
  5. 1 2 3 4 5 "Emeritus Member: Mark Soloway, MD, FACS". Bladder Cancer Advocacy Network. Archived from the original on July 31, 2024. Retrieved July 31, 2024.
  6. ↑ Lee, Jin Seok; Bae, Min Ho; Choi, Sung Ho; Lee, Sang Hun; Cho, Young Sam; Park, Heung Jae; Kwon, Chil Hun; Joo, Kwan Joong (June 2012). "Tumor Establishment Features of Orthotopic Murine Bladder Cancer Models". Korean Journal of Urology. 53 (6): 396–400. doi:10.4111/kju.2012.53.6.396. ISSN   2005-6737. PMC   3382688 . PMID   22741047.
  7. ↑ Cancer Treatment Reports. U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health. 1983. p. 572.
  8. ↑ Seo, Ho Kyung; Shin, Seung-Phil; Jung, Na-Rae; Kwon, Whi-An; Jeong, Kyung-Chae; Lee, Sang-Jin (July 22, 2016). "The establishment of a growth-controllable orthotopic bladder cancer model through the down-regulation of c-myc expression". Oncotarget. 8 (31): 50500–50509. doi:10.18632/oncotarget.10784. ISSN   1949-2553. PMC   5584157 . PMID   28881578.
  9. ↑ "EAU 2020: Five Things I Wish I Would Have Known Earlier in My Career: Lessons from the Mentors - Bladder Cancer". www.urotoday.com. Retrieved August 5, 2024.
  10. ↑ Sweeney, Sean K; Luo, Yi; O’Donnell, Michael A; Assouline, Jose (2016). "Nanotechnology and cancer: improving real-time monitoring and staging of bladder cancer with multimodal mesoporous silica nanoparticles". Cancer Nanotechnology. 7: 3. doi: 10.1186/s12645-016-0015-8 . ISSN   1868-6958. PMC   4846680 . PMID   27217840.
  11. ↑ Balsara, Zarine R.; Li, Xue (April 1, 2017). "Sleeping beauty: awakening urothelium from its slumber". American Journal of Physiology. Renal Physiology. 312 (4): F732 –F743. doi:10.1152/ajprenal.00337.2016. ISSN   1931-857X. PMC   5407074 . PMID   28122714.
  12. ↑ Droller, Michael J. (2004). Urothelial Tumors. PMPH-USA. p. 34. ISBN   978-1-55009-173-1.
  13. ↑ Zingg, E. J.; Wallace, D. M. A. (2012). Bladder Cancer. Springer. pp. 30–33. ISBN   978-1-4471-1362-1.
  14. ↑ Soloway MS, Masters S. Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer, 46(5):1158–1163, 1980.
  15. ↑ Jurewicz, Michael; Soloway, Mark S. (June 2014). "Approaching the optimal transurethral resection of a bladder tumor". Turkish Journal of Urology. 40 (2): 73–77. doi:10.5152/tud.2014.94715. ISSN   2149-3235. PMC   4548374 . PMID   26328154.
  16. ↑ Dirix, L. Y.; Oosterom, A. T. van (1994). "Systemic treatment of bladder cancer". In Banzet, P.; Holland, J. F.; Khayat, D.; Weil, M. (eds.). Cancer Treatment An Update. Springer. p. 58. ISBN   978-2-8178-0767-6.
  17. ↑ Spiers, A. S. D. (December 6, 2012). Chemotherapy and Urological Malignancy. Springer Science & Business Media. p. 375. ISBN   978-1-4471-1332-4.
  18. ↑ Funt, Samuel A.; Rosenberg, Jonathan E. (April 2017). "Systemic, perioperative management of muscle-invasive bladder cancer and future horizons". Nature Reviews. Clinical Oncology. 14 (4): 221–234. doi:10.1038/nrclinonc.2016.188. ISSN   1759-4774. PMC   6054138 . PMID   27874062.
  19. ↑ "Soloway Mark - Faculty - 7th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer". www.erasmus.gr. Archived from the original on August 5, 2024.
  20. ↑ Rotman, Marvin; Rosenthal, C. Julian (1991). "The development of chemotherapy drugs as radiosensitizers: an overview". In Rotman, Marvin; Rosenthal, C. Julian (eds.). Concomitant Continuous Infusion Chemotherapy and Radiation. Berlin: Springer. p. 5. ISBN   978-3-642-84186-6.
  21. ↑ Dutta, Pink R.; Whittington, Richard (2007). "17. Radiation therapy". In Hanno, Philip M.; Wein, Alan J.; Malkowicz, S. Bruce (eds.). Penn Clinical Manual of Urology. Philadelphia: Elsevier. p. 633. ISBN   978-1-4160-3848-1.
  22. ↑ "Mark Soloway MD Chief of Urologic Oncology Memorial Cancer Institute Awarded International Medal". mhs.net. Retrieved August 9, 2024.
  23. ↑ Nieder AM, Soloway MS. Cystoscopy In. Lerner SP, Schoenberg MP, Sternberg CN. Textbook of Bladder Cancer, 2006. Taylor and Francis, England. pgs 179–185.
  24. ↑ Hardeman SW, Wake, R.W., and Soloway MS. The role of prostate specific antigen and transrectal ultrasound in the diagnosis and management of prostate cancer. Postgraduate Medicine, 86:197-208, 1989.
  25. ↑ Hardeman SW, Wake RW, Soloway MS. Two new techniques for evaluating prostate cancer. The role of prostate-specific antigen and transrectal ultrasound. Postgrad Med, 86(2):197–198, 201, 204 passim, 1989.
  26. ↑ Hardeman SW, Causey JQ, Hickey DP, Soloway MS. Transrectal ultrasound for staging prior to radical prostatectomy. Urology, 34(4):175–180, 1989.
  27. ↑ Soloway MS, Obek C. Periprostatic local anesthesia before ultrasound guided prostate biopsy. J Urol, 163(1):172–173, 2000.
  28. ↑ Alavi AS, Soloway MS, Vaidya A, Lynne CM, Gheiler EL. Local anesthesia for ultrasound guided prostate biopsy: a prospective randomized trial comparing 2 methods. J Urol, 166(4):1343–1345, 2001.
  29. ↑ "The Complicated Cost of Prostate Biopsies - American Urological Association". auanews.net. Retrieved March 18, 2025.
  30. ↑ MS, Soloway; R, Sharifi; Z, Wajsman; D, McLeod; DP, Wood; A, Puras-Baez (1995). "Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group". The Journal of Urology. 154 (2 Pt 1). J Urol: 424–428. doi:10.1016/S0022-5347(01)67067-8. ISSN   0022-5347. PMID   7541859.
  31. 1 2 Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood DP, Jr., Puras-Baez A. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol, 167(1):112–116, 2002.
  32. ↑ Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP, Jr., Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol, 154(2 Pt 1):424–428, 1995.
  33. ↑ Watson RB, Civantos F, Soloway MS. Positive surgical margins with radical prostatectomy: detailed pathological analysis and prognosis. Urology, 48(1):80-90, 1996.
  34. ↑ Wieder JA, Soloway MS. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol, 160(2):299-315, 1998.
  35. ↑ Simon MA, Kim S, Soloway MS. Prostate specific antigen recurrence rates are low after radical retropubic prostatectomy and positive margins. J Urol, 175(1):140–144, 2006.
  36. ↑ Shelfo SW, Obek C, Soloway MS. Update on bladder neck preservation during radical retropubic prostatectomy: impact on pathologic outcome, anastomotic strictures, and continence. Urology, 51(1):73-78, 1998.
  37. ↑ Soloway MS, Neulander E. Bladder-neck preservation during radical retropubic prostatectomy. Semin Urol Oncol, 18(1):51-56, 2000.
  38. ↑ Manoharan M, Gomez P, Sved P, Soloway MS. Modified Pfannenstiel approach for radical retropubic prostatectomy. Urology, 64(2):369-371, 2004.
  39. ↑ Savoie M, Soloway MS, Kim SS, Manoharan M. A pelvic drain may be avoided after radical retropubic prostatectomy. J Urol, 170(1):112–114, 2003.
  40. ↑ Araki M, Manoharan M, Vyas S, Nieder AM, Soloway MS. A pelvic drain can often be avoided after radical retropubic prostatectomy--an update in 552 cases. Eur Urol, 50(6):1241–1247, 2006.
  41. ↑ Sachedina N, De Los Santos R, Manoharan M, Soloway MS. Total prostatectomy and lymph node dissection may be done safely without pelvic drainage: an extended experience of over 600 cases. Can J Urol, 16(4):4721–4725, 2009.
  42. ↑ Manoharan M, Gomez P, Soloway MS. Concurrent radical retropubic prostatectomy and inguinal hernia repair through a modified Pfannenstiel incision. BJU Int, 93(9):1203–1206, 2004.
  43. ↑ Manoharan, Murugesan; Vyas, Sachin; Araki, Motoo; Nieder, Alan M.; Soloway, Mark S. (May 30, 2006). "Concurrent radical retropubic prostatectomy and Lichtenstein inguinal hernia repair through a single modified Pfannenstiel incision: a 3-year experience". BJU International. 98 (2). Wiley: 341–344. doi:10.1111/j.1464-410x.2006.06270.x. ISSN   1464-4096. PMID   16879675.
  44. ↑ Neulander EZ, Duncan RC, Tiguert R, Posey JT, Soloway MS. Deferred treatment of localized prostate cancer in the elderly: the impact of the age and stage at the time of diagnosis on the treatment decision. BJU Int, 85(6):699–704, 2000.
  45. ↑ Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int, 101(2):165–169, 2008.
  46. ↑ Ciancio G, Hawke C, Soloway MS. The use of liver transplant techniques to aid in the surgical management of urological tumors. J Urol,164(3 Pt 1):665–672, 2000.
  47. ↑ Cassileth BR, Soloway MS, Vogelzang NJ, Chou JM, Schellhammer PD, Seidmon EJ, Kennealey GT. Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual Life Res, 1(5):323–329, 1992.
  48. ↑ Braslis KG, Santa-Cruz C, Brickman AL, Soloway MS. Quality of life 12 months after radical prostatectomy. Br J Urol, 75(1):48–53, 1995.
  49. ↑ Soloway, Cynthia T.; Soloway, Mark S.; Kim, Sandy S.; Kava, Bruce R. (March 24, 2005). "Sexual, psychological and dyadic qualities of the prostate cancer 'couple'". BJU International . 95 (6). Wiley: 780–785. doi:10.1111/j.1464-410x.2005.05400.x. ISSN   1464-4096. PMID   15794782.
  50. ↑ "AUA Award History | New York Section, AUA". nyaua.com. Archived from the original on August 8, 2024. Retrieved August 7, 2024.
  51. ↑ "St Paul's Medal Winners". www.baus.org.uk. British Association of Urological Surgeons. Retrieved August 9, 2024.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.